stockrow
Friday 6 November 2026
Export ENSC’s income statement to Excel — free account
Ensysce Biosciences, Inc.
ENSC Healthcare Biotechnology
Ensysce Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.1 million, down 2.75% from fiscal 2024.
- Revenue
- −15.1%
- EPS
- +74.7%
- Free cash flow
- +27.5%
Quarter to June 2026, against a year earlier
0.34
0.02
−5.56%
Follow ENSC
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | 4 | 4 | 3 | 2 | 5 | 5 | 5 | +5.2% | 5 | 3 | 5 | (3.9%) | |
| Gross margin, % | — | — | — | — | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 0.0 pt | ||||||
| EBT | — | 0 | 3 | (1) | 0 | (29) | (24) | (11) | (8) | (10) | (13) | +109.3% | ||||||
| EBT margin, % | — | 0.00 | 0.00 | 0.00 | (4.09) | (825.38) | (959.33) | (476.41) | (153.30) | (200.84) | (280.50) | (200.8) pt | ||||||
| Net income | — | 0 | 2 | (1) | 0 | (29) | (24) | (11) | (8) | (10) | (13) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | 0.00 | 0.00 | 0.00 | 897.53 | 630.57 | 210.28 | 14.77 | 7.46 | 1.98 | 0.35 | n/m | |||||
| Earnings | — | 0.00 | 1,272.46 | (631.68) | 12.96 | (5,327.47) | (2,091.39) | (70.31) | (11.45) | (3.98) | (2.76) | n/m | ||||||
| Cash flow | — | (0.20) | (728.41) | (838.12) | (284.77) | (1,471.82) | (1,490.62) | (71.39) | (10.75) | (3.05) | (0.68) | +40.6% | ||||||
| Capex | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.05) | 0.00 | n/m | ||||||
| Free cash flow | — | (0.20) | (728.41) | (838.12) | (284.77) | (1,471.82) | (1,490.62) | (71.39) | (10.75) | (3.10) | (0.68) | +40.9% | ||||||
| Book value | — | 3.97 | 2,941.18 | 2,941.18 | (1,520.18) | (1,456.80) | (335.81) | (4.31) | 4.84 | 1.13 | (0.09) | (14.5%) | ||||||
| Shares, m | — | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 6 | +9.2% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | 0.00 | 26.83 | 0.68 | 1.31 | 1.09 | 0.46 | 0.98 | 5.1 | ||||||
| P/B | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 1.68 | 0.82 | 0.00 | 0.4 | ||||||
| EV/Sales | — | — | — | — | 0.00 | 24.81 | (0.24) | 1.17 | 0.57 | (0.23) | 1.01 | 4.3 | ||||||
| EV/FCF | — | — | — | — | (158.93) | (10.63) | 0.03 | (0.24) | (0.40) | 0.15 | (0.52) | (28.3) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | 0 | (1) | (1) | (1) | (8) | (18) | (11) | (8) | (8) | (9) | +53.6% | |||||
| Capex | — | — | — | — | — | — | — | — | — | 0 | — | — | ||||||
| Free cash flow | — | 0 | (1) | (1) | (1) | (8) | (18) | (11) | (8) | (8) | (9) | +53.9% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | 2 | 1 | (2) | (7) | (1) | (4) | (1) | 3 | 3 | (1) | +2.8% | |||||
| Net debt | — | (2) | (2) | 0 | 1 | (8) | (3) | (1) | (4) | (4) | (1) | +9.5% | ||||||
| Shareholders’ equity | — | 5 | 5 | 5 | (7) | (8) | (4) | (1) | 3 | 3 | (1) | (6.6%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | (0.02) | 1.04 | (0.53) | 0.06 | (356.45) | (224.96) | (247.31) | (192.34) | (155.95) | (295.92) | (155.9) pt | |||||
| ROIC | — | 0.00 | (17.94) | (46.18) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | (0.62) | 42.44 | (21.35) | (6.85) | 403.43 | 411.65 | 454.02 | (585.44) | (324.86) | (1,295.01) | (324.2) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | 4 | 4 | 4 | 4 | 6 | 7 | 8 | 7 | 10 | — | +12.1% | |||||
| Revenue/emp, $m | — | 0.00 | 0.00 | 0.00 | 0.98 | 0.59 | 0.36 | 0.28 | 0.74 | 0.51 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
Ensysce Biosciences, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| VTGN VistaGen Therapeutics, Inc. | $7.3M | — (loss-making) | — (loss-making) | +504.92% (above 0%: growing) | n/m | +22.23% (above 0%: growing) | 100.00% | (904.34%) | Compare |
| SNGX Soligenix Inc. | $7.3M | — (loss-making) | — (loss-making) | −98.89% (below 0%: shrinking) | n/m | +37.83% (above 0%: growing) | 0.00% | 0.00% | Compare |
| XTLB XTL Biopharmaceuticals Ltd. | $7.3M | — (loss-making) | — | −39.32% (below 0%: shrinking) | 0.00% | +46.78% (above 0%: growing) | 0.00% | 0.00% | Compare |
| MTVA MetaVia Inc. | $7.2M | — (loss-making) | — | — | n/m | −22.42% (below 0%: shrinking) | — | 0.00% | Compare |
| ENSC Ensysce Biosciences, Inc. | $7.0M | — (loss-making) | — (loss-making) | −15.10% (below 0%: shrinking) | n/m | +27.50% (above 0%: growing) | 100.00% | (221.28%) | |
| BCLI Brainstorm Cell Therapeutics Inc. | $7.0M | — (loss-making) | — | — | n/m | +74.44% (above 0%: growing) | 0.00% | 0.00% | Compare |
| IMRN IMMURON | $6.9M | — (loss-making) | — | +757.00% (above 0%: growing) | +12.00% (above 0%: growing) | +42.55% (above 0%: growing) | 72.16% | 0.00% | Compare |
| SYBX Synlogic, Inc. | $6.7M | — (loss-making) | — (loss-making) | −95.40% (below 0%: shrinking) | n/m | −277.87% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| KPRX Kiora Pharmaceuticals, Inc. | $6.6M | — (loss-making) | — (loss-making) | −93.64% (below 0%: shrinking) | n/m | +50.06% (above 0%: growing) | 100.00% | 0.00% | Compare |
| Median of peers | $7.1M | — | — | −66.48% | — | +40.19% | 72.16% | 0.00% |
Pay and ownership Proxy statement filed 2 December 2025
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2024 | 442.39k | 442.39k | 0.01 |
| 2023 | 508.58k | 507.19k | 0.09 |
| 2022 | 622.61k | 152.79k | 0.80 |
Ownership
Directors and executive officers, together
2.80%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement